Cargando…

Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development

Many recent studies have reported the onset of a robust antibody response to SARS-CoV-2 infection and highlighted produced antibodies’ specific qualitative and quantitative aspects, relevant for developing antibody-based diagnostic and therapeutic options. In this review, firstly we will report main...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallano, Alessandra, Ascione, Alessandro, Flego, Michela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442988/ https://www.ncbi.nlm.nih.gov/pubmed/34494500 http://dx.doi.org/10.1080/08830185.2021.1929205

Ejemplares similares

Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from Yeast
por: Mallano, Alessandra, et al.
Publicado: (2008)

Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach
por: Flego, Michela, et al.
Publicado: (2005)

Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8(+) T lymphocyte exhaustion
por: Ascione, Alessandro, et al.
Publicado: (2019)

Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity
por: Flego, Michela, et al.
Publicado: (2019)

Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
por: Flego, Michela, et al.
Publicado: (2013)

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
por: Liu, William J., et al.
Publicado: (2017)

SARS CoV- 2 vaccination induces antibodies against cardiolipin
por: Krashias, George, et al.
Publicado: (2022)

An Analysis of the Neutralizing Antibodies against the Main SARS-CoV-2 Variants in Healthcare Workers (HCWs) Vaccinated against or Infected by SARS-CoV-2
por: Immordino, Palmira, et al.
Publicado: (2023)

Generation of human scFvs antibodies recognizing a prion protein epitope expressed on the surface of human lymphoblastoid cells
por: Flego, Michela, et al.
Publicado: (2007)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis
por: Fu, Yu, et al.
Publicado: (2021)

Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
por: Cohen, Samuel A., et al.
Publicado: (2020)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
por: Pang, Natalie Yan-Lin, et al.
Publicado: (2021)

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)

The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development
por: Hajissa, Khalid, et al.
Publicado: (2022)

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2020)

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2021)

Reinfection With SARS-CoV-2: Implications for Vaccines
por: Cohen, Jeffrey I, et al.
Publicado: (2020)

Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase
por: Swanson, Hope D., et al.
Publicado: (2022)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Development of an Inactivated Vaccine against SARS CoV-2
por: Pavel, Shaikh Terkis Islam, et al.
Publicado: (2021)

The development of DNA vaccines against SARS-CoV-2
por: Khalid, Kanwal, et al.
Publicado: (2023)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Selva, Kevin J, et al.
Publicado: (2021)

Perspectives on the development of neutralizing antibodies against SARS-CoV-2
por: Ho, Mitchell
Publicado: (2020)

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
por: Zhao, Shaojuan, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
por: Duan, Li-Jun, et al.
Publicado: (2022)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
por: Markewitz, Robert, et al.
Publicado: (2022)

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
por: Gyang, Tirisham V., et al.
Publicado: (2022)

Long-term observation of antibody titers against SARS-CoV-2 following vaccination
por: Sugiyama, Kazuo, et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection
por: Baerends, Eva A.M., et al.
Publicado: (2023)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Development of an Effective Neutralizing Antibody Assay for SARS-CoV-2 Diagnosis
por: Liu, Zhigang, et al.
Publicado: (2023)

SARS-CoV-2 infection in children and implications for vaccination
por: Nathanielsz, Jordan, et al.
Publicado: (2022)

Progress and Prospects on Vaccine Development against SARS-CoV-2
por: Zhang, Jinyong, et al.
Publicado: (2020)

Targets and strategies for vaccine development against SARS-CoV-2
por: Malik, Jonaid Ahmad, et al.
Publicado: (2021)

Development of DNA Vaccine Candidate against SARS-CoV-2
por: Wang, Xingyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sv7740t65akirkbnhuhgc93jet